Document Detail


How can attrition rates be reduced in cancer drug discovery?
MedLine Citation:
PMID:  23373702     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Attrition is a major issue in anticancer drug development with up to 95% of drugs tested in Phase I trials not reaching a marketing authorisation making the drug development process enormously costly and inefficient. It is essential that this problem is addressed throughout the whole drug development process to improve efficiency which will ultimately result in increased patient benefit with more profitable drugs. The approach to reduce cancer drug attrition rates must be based on three pillars. The first of these is that there is a need for new pre-clinical models which can act as better predictors of success in clinical trials. Furthermore, clinical trials driven by tumour biology with the incorporation of predictive and pharmacodynamic biomarkers would be beneficial in drug development. Finally, there is a need for increased collaboration to combine the unique strengths between industry, academia and regulators to ensure that the needs of all stakeholders are met.
Authors:
Lucas Moreno; Andrew Dj Pearson
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-4
Journal Detail:
Title:  Expert opinion on drug discovery     Volume:  -     ISSN:  1746-045X     ISO Abbreviation:  Expert Opin Drug Discov     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101295755     Medline TA:  Expert Opin Drug Discov     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Paediatric Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust , Downs Road, Sutton SM2 5PT , UK +44 0 208 661 3678 ; +44 0 208 661 3617 ; lucas.moreno@icr.ac.uk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dopamine D2 Receptor Activation Leads To An Upregulation Of Glial Cell Line-Derived Neurotrophic Fac...
Next Document:  Modification of surfaces by chemical transfer printing using chemically patterned stamps.